Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators

The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-bl...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1999-08, Vol.84 (3), p.289
Main Authors: Oparil, S, Levine, J H, Zuschke, C A, Gradman, A H, Ripley, E, Jones, D W, Hardison, J D, Cushing, D J, Prasad, R, Michelson, E L
Format: Article
Language:English
Subjects:
Adult
Angiotensin Receptor Antagonists
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Benzimidazoles - administration & dosage
Benzimidazoles - adverse effects
Benzimidazoles - therapeutic use
Biphenyl Compounds - administration & dosage
Biphenyl Compounds - adverse effects
Biphenyl Compounds - therapeutic use
Diuretics
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide - therapeutic use
Hypertension - drug therapy
Least-Squares Analysis
Male
Middle Aged
Sodium Chloride Symporter Inhibitors - therapeutic use
Tetrazoles
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-blind, placebo-controlled study. Patients with sitting diastolic blood pressure (BP) > or =110 mm Hg during the placebo run-in received HCTZ 12.5 mg once daily for 1 week. Those with sitting diastolic BP >95 mm Hg after the HCTZ run-in were randomized (2:1) to receive candesartan cilexetil 8 mg once daily (n = 141) or placebo (n = 76), plus HCTZ 12.5 mg. After 1 week of double-blind treatment, patients with sitting diastolic BP > or =90 mm Hg were uptitrated to candesartan cilexetil 16 mg once daily or matching placebo, plus HCTZ 12.5 mg; 84% required uptitration. Primary efficacy measurement was a change in trough (24+/-3 hours after treatment) sitting diastolic BP from the end of the HCTZ run-in to double-blind week 4. Mean changes in systolic and diastolic BP were significantly greater with candesartan cilexetil than with placebo, -11.3/-9.1 mm Hg versus -4.1/-3.1 mm Hg, p
ISSN:0002-9149